Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
Open Access
- 27 April 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3151
Abstract
The goal of treatment for Alzheimer’s dementia (AD) is the restoration of normal cognition. No drug regimen has ever achieved this. This article suggests that curing AD may be achieved by combination therapy as follows. First, with intranasal insulin to augment the body’s natural counter-reaction to the changes in brain cell-types that produced the dementia. Second, with edaravone to decrease free radicals, which are increased and causal in AD. Third, as described elsewhere, with one or two drugs from among pioglitazone, fluoxetine, and lithium, which address the brain cell-types whose changed functions cause the dementia. Insulin restores cerebral glucose, which is the main nutrient for brain neurons whose depletion is responsible for the dementia; and edaravone decreases ROS, which are intrinsic causes of neuropathology in AD. This combination of drugs is a potential cure for many patients with AD, and should be tested in a clinical trial.Keywords
This publication has 69 references indexed in Scilit:
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2012
- Insulin Promotes Glycogen Storage and Cell Proliferation in Primary Human AstrocytesPLOS ONE, 2011
- Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's diseaseThe Lancet Neurology, 2011
- Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 DiabetesArchives of Neurology, 2011
- Brain Insulin Action Regulates Hypothalamic Glucose Sensing and the Counterregulatory Response to HypoglycemiaDiabetes, 2010
- Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's DiseasePLOS ONE, 2010
- Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2008
- Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In VivoNeuron, 2008
- Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidaseJournal of Clinical Investigation, 2007
- Modest decrements in plasma glucose concentration cause early impairment in cognitive function and later activation of glucose counterregulation in the absence of hypoglycemic symptoms in normal man.Journal of Clinical Investigation, 1988